119 related articles for article (PubMed ID: 38507581)
1. Long-term prediction by DNA methylation of high-grade cervical intraepithelial neoplasia: Results of the ARTISTIC cohort.
Gilham C; Nedjai B; Scibior-Bentkowska D; Reuter C; Banwait R; Brentnall AR; Cuzick J; Peto J; Lorincz AT
Int J Cancer; 2024 Jul; 155(1):81-92. PubMed ID: 38507581
[TBL] [Abstract][Full Text] [Related]
2. Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping.
Hernández-López R; Lorincz AT; Torres-Ibarra L; Reuter C; Scibior-Bentkowska D; Warman R; Nedjai B; Mendiola-Pastrana I; León-Maldonado L; Rivera-Paredez B; Ramírez-Palacios P; Lazcano-Ponce E; Cuzick J; Salmerón J;
Clin Epigenetics; 2019 Oct; 11(1):140. PubMed ID: 31606044
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation testing with S5 for triage of high-risk HPV positive women.
Adcock R; Nedjai B; Lorincz AT; Scibior-Bentkowska D; Banwait R; Torrez-Martinez N; Robertson M; Cuzick J; Wheeler CM;
Int J Cancer; 2022 Oct; 151(7):993-1004. PubMed ID: 35477862
[TBL] [Abstract][Full Text] [Related]
4. Effective methylation triage of HPV positive women with abnormal cytology in a middle-income country.
Ramírez AT; Sánchez GI; Nedjai B; Agudelo MC; Brentnall AR; Cuschieri K; Castañeda KM; Cuzick J; Lorincz AT;
Int J Cancer; 2021 Mar; 148(6):1383-1393. PubMed ID: 33006394
[TBL] [Abstract][Full Text] [Related]
5. Complementarity between miRNA expression analysis and DNA methylation analysis in hrHPV-positive cervical scrapes for the detection of cervical disease.
Babion I; De Strooper LMA; Luttmer R; Bleeker MCG; Meijer CJLM; Heideman DAM; Wilting SM; Steenbergen RDM
Epigenetics; 2019 Jun; 14(6):558-567. PubMed ID: 30955437
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation marker for the triage of hrHPV positive women in cervical cancer screening: Real-world evidence in Taiwan.
Chang CL; Ho SC; Su YF; Juan YC; Huang CY; Chao AS; Hsu ZS; Chang CF; Fwu CW; Chang TC
Gynecol Oncol; 2021 May; 161(2):429-435. PubMed ID: 33757653
[TBL] [Abstract][Full Text] [Related]
7. Clinical performance of methylation as a biomarker for cervical carcinoma in situ and cancer diagnosis: A worldwide study.
Banila C; Lorincz AT; Scibior-Bentkowska D; Clifford GM; Kumbi B; Beyene D; Wheeler CM; Cuschieri K; Cuzick J; Nedjai B
Int J Cancer; 2022 Jan; 150(2):290-302. PubMed ID: 34562270
[TBL] [Abstract][Full Text] [Related]
8. HPV33 DNA methylation measurement improves cervical pre-cancer risk estimation of an HPV16, HPV18, HPV31 and \textit{EPB41L3} methylation classifier.
Brentnall AR; Vasiljevic N; Scibior-Bentkowska D; Cadman L; Austin J; Cuzick J; Lorincz AT
Cancer Biomark; 2015; 15(5):669-75. PubMed ID: 26406956
[TBL] [Abstract][Full Text] [Related]
9. Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytology-screened referral population.
Leeman A; Del Pino M; Marimon L; Torné A; Ordi J; Ter Harmsel B; Meijer CJLM; Jenkins D; Van Kemenade FJ; Quint WGV
Int J Cancer; 2019 Jan; 144(1):160-168. PubMed ID: 30098013
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
[No Abstract] [Full Text] [Related]
11. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
12. Defining hrHPV genotypes in cervical intraepithelial neoplasia by laser capture microdissection supports reflex triage of self-samples using HPV16/18 and FAM19A4/miR124-2 methylation.
Leeman A; Ebisch RMF; Kasius A; Bosgraaf RP; Jenkins D; van de Sandt MM; de Strooper LMA; Heideman DAM; Snijders PJF; Massuger LFAG; Bekkers RLM; Meijer CJLM; van Kemenade FJ; Quint WGV; Melchers WJG
Gynecol Oncol; 2018 Nov; 151(2):311-318. PubMed ID: 30219239
[TBL] [Abstract][Full Text] [Related]
13. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
14. Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient population (COMETH study).
Luttmer R; De Strooper LM; Berkhof J; Snijders PJ; Dijkstra MG; Uijterwaal MH; Steenbergen RD; van Kemenade FJ; Rozendaal L; Helmerhorst TJ; Verheijen RH; Ter Harmsel WA; Van Baal WM; Graziosi PG; Quint WG; Heideman DA; Meijer CJ
Int J Cancer; 2016 Feb; 138(4):992-1002. PubMed ID: 26317579
[TBL] [Abstract][Full Text] [Related]
15. Validation of a DNA methylation HPV triage classifier in a screening sample.
Lorincz AT; Brentnall AR; Scibior-Bentkowska D; Reuter C; Banwait R; Cadman L; Austin J; Cuzick J; Vasiljević N
Int J Cancer; 2016 Jun; 138(11):2745-51. PubMed ID: 26790008
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation markers as a triage test for identification of cervical lesions in a high risk human papillomavirus positive screening cohort.
van Leeuwen RW; Oštrbenk A; Poljak M; van der Zee AGJ; Schuuring E; Wisman GBA
Int J Cancer; 2019 Feb; 144(4):746-754. PubMed ID: 30259973
[TBL] [Abstract][Full Text] [Related]
17. Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women.
Hesselink AT; Heideman DA; Steenbergen RD; Coupé VM; Overmeer RM; Rijkaart D; Berkhof J; Meijer CJ; Snijders PJ
Clin Cancer Res; 2011 Apr; 17(8):2459-65. PubMed ID: 21389098
[TBL] [Abstract][Full Text] [Related]
18. A DNA methylation classifier of cervical precancer based on human papillomavirus and human genes.
Brentnall AR; Vasiljević N; Scibior-Bentkowska D; Cadman L; Austin J; Szarewski A; Cuzick J; Lorincz AT
Int J Cancer; 2014 Sep; 135(6):1425-32. PubMed ID: 24535756
[TBL] [Abstract][Full Text] [Related]
19. The WID-CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and invasive cervical cancer.
Barrett JE; Sundström K; Jones A; Evans I; Wang J; Herzog C; Dillner J; Widschwendter M
Genome Med; 2022 Oct; 14(1):116. PubMed ID: 36258199
[TBL] [Abstract][Full Text] [Related]
20. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.
Kjær SK; Frederiksen K; Munk C; Iftner T
J Natl Cancer Inst; 2010 Oct; 102(19):1478-88. PubMed ID: 20841605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
